{"altmetric_id":4054657,"counts":{"readers":{"mendeley":6,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["326537550731407"],"posts_count":2},"total":{"posts_count":7},"twitter":{"unique_users_count":4,"unique_users":["sean_tiernan","BindingSiteHaem","jose6xxx","DaeKang74"],"posts_count":5}},"selected_quotes":["Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma... #myeloma #cancer"],"citation":{"abstract":"The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.","altmetric_jid":"4f6fa6393cf058f610008aad","authors":["Samaras, Panagiotis","Bargetzi, Mario","Betticher, Daniel","Duchosal, Michel","Heim, Dominik","Hess, Urs","Ketterer, Nicolas","Lerch, Erika","Matthes, Thomas","Mey, Ulrich","Pabst, Thomas","Taverna, Christian","Zander, Thilo","Renner, Christoph","P Samaras","M Bargetzi","D Betticher","M Duchosal","D Heim","U Hess","N Ketterer","E Lerch","T Matthes","U Mey","T Pabst","C Taverna","T Zander","C Renner"],"doi":"10.4414\/smw.2015.14100","first_seen_on":"2015-05-25T00:23:12+00:00","funders":["niehs"],"issns":["1424-3997","1424-7860"],"journal":"Swiss Medical Weekly","last_mentioned_on":1490612414,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25999239?dopt=Abstract","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25999239?utm_content=19140314&utm_medium=social&utm_source=twitter","http:\/\/blog.smw.ch\/current-status-and-updated-recommendations-for-diagnosis-and-treatment-of-plasma-cell-myeloma-in-switzerland\/","https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25999239?utm_content=50850766&utm_medium=social&utm_source=twitter"],"pmid":"25999239","pubdate":"2015-02-21T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["medicine"],"title":"Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.","type":"article","uri":"http:\/\/doi.emh.ch\/smw.2015.14100","volume":"145","mendeley_url":"http:\/\/www.mendeley.com\/research\/current-status-updated-recommendations-diagnosis-treatment-plasma-cell-myeloma-switzerland"},"altmetric_score":{"score":2.95,"score_history":{"1y":0.5,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":2.95},"context_for_score":{"all":{"total_number_of_other_articles":8422812,"mean":7.0866213065837,"rank":3313321,"this_scored_higher_than_pct":60,"this_scored_higher_than":5097621,"rank_type":"exact","sample_size":8422812,"percentile":60},"similar_age_3m":{"total_number_of_other_articles":221350,"mean":8.6483078215849,"rank":74369,"this_scored_higher_than_pct":66,"this_scored_higher_than":146559,"rank_type":"exact","sample_size":221350,"percentile":66},"this_journal":{"total_number_of_other_articles":583,"mean":2.4544364261168,"rank":140,"this_scored_higher_than_pct":75,"this_scored_higher_than":443,"rank_type":"exact","sample_size":583,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":6,"mean":1.34,"rank":2,"this_scored_higher_than_pct":66,"this_scored_higher_than":4,"rank_type":"exact","sample_size":6,"percentile":66}}},"demographics":{"poster_types":{"member_of_the_public":4},"users":{"twitter":{"cohorts":{"Members of the public":4}},"mendeley":{"by_status":{"Researcher":4,"Other":2},"by_discipline":{"Medicine and Dentistry":2,"Immunology and Microbiology":1,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":2}}},"geo":{"twitter":{"GB":2,"ES":1}}},"posts":{"facebook":[{"title":"Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in...","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=879609138757576&id=326537550731407","license":"public","citation_ids":[4054657],"posted_on":"2015-02-21T16:07:37+00:00","summary":"The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss e","author":{"name":"Swiss Medical Weekly","url":"https:\/\/www.facebook.com\/326537550731407","facebook_wall_name":"Swiss Medical Weekly","image":"https:\/\/graph.facebook.com\/326537550731407\/picture","id_on_source":"326537550731407"}},{"title":"Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in...","url":"https:\/\/www.facebook.com\/326537550731407\/posts\/879608905424266","license":"public","citation_ids":[4054657],"posted_on":"2015-02-21T16:06:57+00:00","summary":"The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss e","author":{"name":"Swiss Medical Weekly","url":"https:\/\/www.facebook.com\/326537550731407","facebook_wall_name":"Swiss Medical Weekly","image":"https:\/\/graph.facebook.com\/326537550731407\/picture","id_on_source":"326537550731407"}}],"twitter":[{"url":"https:\/\/twitter.com\/sean_tiernan\/status\/602630841626333185","license":"datasift","citation_ids":[4054657],"posted_on":"2015-05-25T00:22:43+00:00","author":{"name":"Sean Tiernan","url":"http:\/\/mylifewithmyeloma.blogspot.com","image":"https:\/\/pbs.twimg.com\/profile_images\/1552303712\/Sean_G__normal.png","description":"Professional Photographer covering portraiture, fashion, glamour and product photography. I'm also a Cancer patient  having ongoing treatment for Myeloma.","id_on_source":"sean_tiernan","tweeter_id":"36006306","geo":{"lt":53.1905,"ln":-2.89189,"country":"GB"},"followers":411},"tweet_id":"602630841626333185"},{"url":"https:\/\/twitter.com\/BindingSiteHaem\/status\/626407821907783680","license":"datasift","citation_ids":[4054657],"posted_on":"2015-07-29T15:03:57+00:00","author":{"name":"Binding Site","url":"http:\/\/www.bindingsite.com","image":"https:\/\/pbs.twimg.com\/profile_images\/466145479625949187\/lZH6z1lj_normal.png","description":"Clinical utility of free light chains (Freelite) & heavy\/light chains (Hevylite) in monoclonal gammopathy #myeloma #nephrology Disclaimer http:\/\/hub.am\/1jLoIuK","id_on_source":"BindingSiteHaem","tweeter_id":"875434993","geo":{"lt":52.48142,"ln":-1.89983,"country":"GB"},"followers":827},"tweet_id":"626407821907783680"},{"url":"https:\/\/twitter.com\/jose6xxx\/status\/626471945844977664","license":"datasift","rt":["BindingSiteHaem"],"citation_ids":[4054657],"posted_on":"2015-07-29T19:18:45+00:00","author":{"name":"Jos\u00e9 L. Garc\u00eda","url":"https:\/\/es.linkedin.com\/in\/jose0","image":"https:\/\/pbs.twimg.com\/profile_images\/610876993354264577\/iveN_9iL_normal.jpg","description":"Especialista en Bioqu\u00edmica Cl\u00ednica y An\u00e1lisis Cl\u00ednicos. Complejo Hospitalario Universitario de Granada","id_on_source":"jose6xxx","tweeter_id":"406496525","geo":{"lt":40,"ln":-4,"country":"ES"},"followers":495},"tweet_id":"626471945844977664"},{"url":"https:\/\/twitter.com\/DaeKang74\/status\/629519383790944256","license":"datasift","rt":["BindingSiteHaem"],"citation_ids":[4054657],"posted_on":"2015-08-07T05:08:11+00:00","author":{"name":"DaeSung KANG","image":"http:\/\/pbs.twimg.com\/profile_images\/628444580204023808\/E6T9KnAX_normal.jpg","description":"DOW Biomedica inc. South Korea","id_on_source":"DaeKang74","tweeter_id":"3305550451","followers":2},"tweet_id":"629519383790944256"},{"url":"http:\/\/twitter.com\/BindingSiteHaem\/statuses\/846315924063997953","license":"gnip","citation_ids":[4054657],"posted_on":"2017-03-27T11:00:14+00:00","author":{"name":"Binding Site","url":"http:\/\/www.bindingsite.com","image":"https:\/\/pbs.twimg.com\/profile_images\/466145479625949187\/lZH6z1lj_normal.png","description":"Clinical utility of free light chains (Freelite) & heavy\/light chains (Hevylite) in monoclonal gammopathy #myeloma #nephrology Disclaimer http:\/\/hub.am\/1jLoIuK","id_on_source":"BindingSiteHaem","tweeter_id":"875434993","geo":{"lt":52.48142,"ln":-1.89983,"country":"GB"},"followers":827},"tweet_id":"846315924063997953"}]}}